In short
Clinical trials of Golodirsen are studying people with Duchenne Muscular Dystrophy who are amenable to exon 53 skipping. These studies look at whether Golodirsen can help with movement and muscle function, and they also assess safety and treatment effects.
Key points
- Golodirsen is being studied in clinical trials for Duchenne Muscular Dystrophy, especially in patients who are amenable to exon 53 skipping. The main trial in the source data is a Phase 3 study with 328 participants. It compares Golodirsen-related treatment with placebo and looks at walking and muscle function. The main outcome is change in 4-step ascend velocity after 96 weeks. The listed trial is completed and focuses on patients whose disease fits this exon-skipping approach.
Trial overview
The source data describe one interventional study, which means researchers gave study treatments and compared results between groups. The study was designed for patients with Duchenne Muscular Dystrophy who were amenable to exon 45 or exon 53 skipping.
The trial title says it was a research study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patients. In the intervention list, Golodirsen appears as one of the study drugs under the name GOLODIRSEN (SRP-4053).
Who was studied
The study included patients with Duchenne Muscular Dystrophy who were amenable to exon 45 or 53 skipping. “Amenable” means the patient’s condition may fit the study approach for that specific exon-skipping strategy.
The data do not give more details about age, sex, or other entry rules. The enrollment number shows that 328 people took part in the trial.
Trial design and treatment groups
This was a Phase 3 trial, which is a later stage of testing used to study how well a treatment works in a larger group of patients. The intervention list shows three study arms: CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), and 0.9% sodium chloride, which served as the comparison treatment.
The brief summary says the study compared the combined active group with placebo to evaluate the effect on ambulation and muscle function. Placebo means a comparison treatment that does not contain the active study drug.
The study also included a double-blind period, meaning that during that part of the trial, patients and study staff did not know who was receiving active treatment or placebo.
What was measured
The main outcome was change from baseline at Week 96 in 4-step ascend velocity. Baseline is the starting point before treatment begins, and 4-step ascend velocity is a test of how fast a patient can climb four steps.
This outcome was chosen to measure ambulation, which means the ability to walk, and overall muscle function. In simple terms, the study wanted to see whether treatment could help patients move better over time.
Trial status and size
The trial NCT02500381 is listed as Completed. The enrollment number was 328 participants, which shows it was a fairly large study for this condition.
Because the source data only include one trial, the article focuses on this single Phase 3 study of Golodirsen in Duchenne Muscular Dystrophy patients who fit exon-skipping criteria.